How GPCR agonists, including antibodies, are shaping the future of metabolic care
Drug Target Review
DECEMBER 4, 2024
The MC4R-based ConfoGen was used to immunize llamas, resulting in an immune response that generated a highly diverse panel of MC4R-specific agonists. In addition to generating agonistic antibodies, Confo is also successfully applying the ConfoBody/ConfoChimer technology to drugging GPCR with small molecules.
Let's personalize your content